BS_MWWZBQ60
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 17.608409986859396
- age_years
- 11.836
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168559 | — | — | 0.818 |
| 2 | BS_30VC3R2Q | Diffuse intrinsic pontine glioma | — | 0.813 |
| 3 | fec205e8-388c-47a2-9400-ec9fe2e0fab1 | — | — | 0.807 |
| 4 | EPT0578 | EPN | Posterior Fossa EPN | 0.799 |
| 5 | MNG223 | — | — | 0.790 |
| 6 | TCGA-CV-6961-01A-21R-1915-07 | — | — | 0.772 |
| 7 | TCGA-77-7338-01A-11R-2045-07 | — | cohortSQ2 | 0.772 |
| 8 | SRR1313160 | — | E | 0.768 |
| 9 | TCGA-60-2707-01A-01R-0851-07 | — | cohortSQ1 | 0.764 |
| 10 | sclcRT1198_S58.txt | — | cohortSC | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HYPOXIA | 0.566 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.426 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.344 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.323 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.296 | Inavolisib | — uncovered |
| COAGULATION | 0.272 | Binimetinib | — uncovered |
| MYOGENESIS | 0.264 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.256 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.247 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.245 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.228 | Inavolisib | — uncovered |
| COMPLEMENT | 0.222 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.222 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.214 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.211 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.196 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.195 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.192 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |